| 1 |
NCT00014599 |
Completed |
Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva |
|
|
Interventional
|
Phase 2 |
- European Organisation for Research and Treatment of Cancer - EORTC
- European Organisation for Research and Treatment of Cancer - EORTC
|
Other |
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
31 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00014599 |
EORTC-55985 |
|
February 2001 |
February 2005 |
|
January 27, 2003 |
September 24, 2012 |
|
- Universitair Ziekenhuis Antwerpen
Edegem, Belgium - U.Z. Gasthuisberg
Leuven, Belgium - Centre Henri Becquerel
Rouen, France - (and 11 more...)
|
|
| 2 |
NCT01406769 |
Active, not recruiting |
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy |
- Lymphedema
- Perioperative/Postoperative Complications
- Stage IA Vulvar Cancer
- (and 7 more...)
|
- Procedure: Bioelectric Impedance Analysis
- Procedure: Lymphadenectomy
- Procedure: Therapeutic Conventional Surgery
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Frequency and severity of adverse events using Common Terminology Criteria for Adverse Events (CTCAE) v4.0
- Sensitivity, specificity, and feasibility of bioimpedance technology as compared to clinically derived measurements (limb volume and Stemmer Sign)
|
120 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01406769 |
GOG-0269
NCI-2011-03798
CDR0000706551
U10CA101165 |
|
July 2012 |
July 2017 |
|
August 1, 2011 |
May 4, 2017 |
|
- University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States - Saint Vincent Hospital and Health Care Center
Indianapolis, Indiana, United States - (and 8 more...)
|
|
| 3 |
NCT00028951 |
Completed |
Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva |
- Lymphedema
- Perioperative/Postoperative Complications
- Vulvar Cancer
|
- Drug: fibrin sealant
- Procedure: surgical wound closure
|
Interventional
|
Phase 3 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Primary Purpose: Supportive Care
|
- Incidence of lymphedema of the lower extremity at 1 week, 6 weeks, 3 months, and 6 months postoperatively
- Frequency of surgical complications at 1 week, 6 weeks, 3 months, and 6 months postoperatively
|
|
Female |
18 Years and older (Adult, Older Adult) |
NCT00028951 |
CDR0000069149
GOG-0195
NCI-P01-0201 |
|
January 2003 |
December 2005 |
|
January 27, 2003 |
July 9, 2013 |
|
- Comprehensive Cancer Center at University of Alabama at Birmingham
Birmingham, Alabama, United States - CCOP - Western Regional, Arizona
Phoenix, Arizona, United States - Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, United States - (and 46 more...)
|
|
| 4 |
NCT00068406 |
Completed
Has Results |
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva |
- Stage III Vulvar Cancer
- Stage IVB Vulvar Cancer
- Vulvar Squamous Cell Carcinoma
|
- Radiation: 3-Dimensional Conformal Radiation Therapy
- Drug: Cisplatin
- Procedure: Conventional Surgery
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Clinical and Pathologic Response
- Treatment-Related Adverse Effects (Grade 3 or Higher) During Study Treatment Period
|
61 |
Female |
Child, Adult, Older Adult |
NCT00068406 |
GOG-0205
NCI-2009-00582
CDR0000322259
U10CA027469 |
|
January 2005 |
December 2010 |
January 20, 2012 |
September 11, 2003 |
November 20, 2017 |
October 17, 2017 |
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Banner Thunderbird Medical Center
Glendale, Arizona, United States - Banner Good Samaritan Medical Center
Phoenix, Arizona, United States - (and 100 more...)
|
|
| 5 |
NCT01595061 |
Recruiting |
Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva |
- Stage IIIA Vulvar Cancer AJCC v7
- Stage IIIB Vulvar Cancer AJCC v7
- Stage IIIC Vulvar Cancer AJCC v7
- (and 2 more...)
|
- Drug: Cisplatin
- Drug: Gemcitabine Hydrochloride
- Radiation: Intensity-Modulated Radiation Therapy
- Procedure: Therapeutic Conventional Surgery
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete pathologic response evaluated as the frequency of complete clinical and pathologic response after primary therapy
- Complete clinical response, defined as no clinical/radiographic evidence of primary disease (vulvar or groin) following chemo-radiation therapy
- Incidence and severity of adverse effects tabulated based on the Common Terminology Criterial for Adverse Events (CTCAE) v 4.0
- (and 4 more...)
|
52 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01595061 |
GOG-0279
NCI-2012-01964
CDR0000732793
U10CA180868
U10CA027469 |
|
July 2, 2012 |
September 30, 2019 |
|
May 9, 2012 |
May 10, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - (and 180 more...)
|
|
| 6 |
NCT00577317 |
Terminated |
Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer |
- Lymphedema
- Stage 0 Cervical Cancer
- Stage 0 Uterine Corpus Cancer
- (and 16 more...)
|
- Procedure: Management of Therapy Complications
- Other: Quality-of-Life Assessment
|
Interventional
|
Phase 3 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Supportive Care
|
- Lower-extremity volumes for both unaffected and affected legs
- Quality of life (QOL) and functional status as assessed by the Lymphedema Questionnaire
- Compliance with treatment as assessed by the number of days per week using MLD or Flexitouch system and duration/day of MLD and Flexitouch system treatment
- (and 4 more...)
|
2 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00577317 |
GOG-0236
NCI-2009-00602
CDR0000579834
U10CA101165 |
|
December 2007 |
July 2009 |
|
December 20, 2007 |
December 31, 2014 |
|
- Gynecologic Oncology Group
Philadelphia, Pennsylvania, United States
|
|
| 7 |
NCT01304667 |
Completed |
Chemo- and Radiotherapy in Epithelial Vulvar Cancer |
- Radio/Chemotherapy in Node Positive Advanced Vulvar Cancer
|
|
Observational
|
|
- AGO Study Group
- medac GmbH
- Philipps University Marburg Medical Center
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Determination of several specific characteristics
|
1618 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01304667 |
AGO-VOP.1 / CARE |
CARE |
February 2011 |
June 2012 |
June 2012 |
February 25, 2011 |
May 10, 2016 |
|
- University Medical Center Hamburg-Eppendorf
Hamburg, Germany
|
|
| 8 |
NCT00956670 |
Active, not recruiting |
Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer |
- Lymphedema
- Stage IA Cervical Cancer
- Stage IA Uterine Corpus Cancer
- (and 11 more...)
|
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
- Procedure: Study of High Risk Factors
- (and 3 more...)
|
Interventional
|
Not Applicable |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Incidence of lymphedema, assessed through volumetric measurements using serial circumferential measurements performed from 10 cm above the heel to the inguinal crease at 10 cm intervals
- Risk factors for the development of lower extremity lymphoma in patients with endometrial cancers
- Patient self-reported symptoms
- (and 2 more...)
|
1055 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00956670 |
GOG-0244
NCI-2011-01932
CDR0000646813
U10CA101165
UG1CA189867 |
LEG |
June 2012 |
April 2015 |
|
August 11, 2009 |
May 8, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Gynecologic Oncology Group of Arizona
Phoenix, Arizona, United States - Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, United States - (and 210 more...)
|
|
| 9 |
NCT00092521 |
Completed
Has Results |
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) |
- Cervical Cancer
- Genital Warts
|
- Biological: V501
- Biological: Comparator: Placebo
- Biological: Human Papillomavirus (HPV) 16 Monovalent
|
Interventional
|
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer
- Incidence of HPV 6/11/16/18-related External Genital Lesions (EGL) [Genital Warts, Vulvar/Vaginal Intraepithelial Neoplasia (Any Grade), Vulvar/Vaginal Cancer]
|
5759 |
Female |
16 Years to 23 Years (Child, Adult) |
NCT00092521 |
V501-013
2004_081 |
|
December 2001 |
July 2007 |
January 2009 |
September 28, 2004 |
September 25, 2015 |
November 20, 2009 |
|
|
| 10 |
NCT01500512 |
Active, not recruiting |
Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection |
- Stage I Vulvar Cancer
- Stage II Vulvar Cancer
- Stage III Vulvar Cancer
- Vulvar Squamous Cell Carcinoma
|
- Other: Clinical Observation
|
Observational
|
|
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
|
- Safety of sentinel lymph node dissection
|
148 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01500512 |
GOG-0270
NCI-2012-00100
CDR0000721346
U10CA180868
U10CA027469 |
GROINSS-V |
January 3, 2012 |
July 1, 2015 |
|
December 28, 2011 |
August 24, 2017 |
|
- University of Arizona Cancer Center at Saint Joseph's
Phoenix, Arizona, United States - Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, United States - UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, United States - (and 34 more...)
|
|
| 11 |
NCT03220009 |
Not yet recruiting |
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma |
- Cervical Carcinoma
- Esophageal Carcinoma
- Mucosal Melanoma
- (and 14 more...)
|
- Procedure: Conventional Surgery
- Biological: Ipilimumab
- Other: Laboratory Biomarker Analysis
- (and 3 more...)
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recurrence free survival (RFS)
- Distant recurrence-free survival (DRFS)
- Incidence of adverse events evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- (and 2 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03220009 |
NCI-2017-01239
A091603
U10CA180821 |
|
November 3, 2017 |
July 1, 2021 |
July 1, 2021 |
July 18, 2017 |
October 17, 2017 |
|
- Alliance for Clinical Trials in Oncology
Boston, Massachusetts, United States
|
|
| 12 |
NCT00003325 |
Completed |
Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva |
|
- Procedure: Sentinel lymph node mapping
|
Interventional
|
Phase 3 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Predictive value of negative sentinel lymph nodes in vulvar cancer patients
|
515 |
Female |
Child, Adult, Older Adult |
NCT00003325 |
GOG-0173
CDR0000066277
NCI-2009-00579 |
|
December 1999 |
July 2013 |
|
January 27, 2003 |
May 29, 2015 |
|
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - Todd Cancer Institute at Long Beach Memorial Medical Center
Long Beach, California, United States - UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States - (and 69 more...)
|
|
| 13 |
NCT00504023 |
Completed
Has Results |
Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva |
|
- Drug: imiquimod
- Procedure: biopsy
- Procedure: therapeutic conventional surgery
|
Interventional
|
Not Applicable |
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
- Ohio State University
- Memorial Sloan Kettering Cancer Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Clinical and Histologic Remission
|
8 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00504023 |
07-029
MSKCC-07029 |
|
April 2007 |
January 2018 |
January 2018 |
July 19, 2007 |
June 6, 2018 |
May 8, 2018 |
- Memorial Sloan Kettering Cancer Center
New York, New York, United States - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
|
|
| 14 |
NCT00006096 |
Terminated |
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva |
|
- Drug: cisplatin
- Radiation: radiation therapy
|
Interventional
|
Phase 3 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
|
Female |
Child, Adult, Older Adult |
NCT00006096 |
CDR0000068103
GOG-0185 |
|
March 2001 |
January 2003 |
|
September 3, 2003 |
June 10, 2013 |
|
- Community Hospital of Los Gatos
Los Gatos, California, United States - Chao Family Comprehensive Cancer Center
Orange, California, United States - University of Colorado Cancer Center
Denver, Colorado, United States - (and 27 more...)
|
|
| 15 |
NCT02595879 |
Suspended |
Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vulvar Cancer |
- Cervical Adenocarcinoma
- Cervical Adenosquamous Carcinoma
- Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- (and 15 more...)
|
- Drug: Cisplatin
- Radiation: External Beam Radiation Therapy
- Radiation: High-Dose Rate Brachytherapy
- (and 5 more...)
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of dose-limiting toxicity (DLT) to determine maximum tolerated dose, defined as the dose level where < 2/6 DLTs are observed
- Incidence of toxicity, evaluated using the NCI CTCAE version 4.0 (version 5.0 beginning April 1, 2018)
- Oral bioavailability of the oral form of the triapine
- (and 5 more...)
|
64 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02595879 |
NCI-2015-01907
UPCI 15-157
15-157
9892
UM1CA186690 |
|
May 27, 2016 |
December 31, 2018 |
|
November 4, 2015 |
April 26, 2018 |
|
- University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, United States - University of Virginia Cancer Center
Charlottesville, Virginia, United States
|
|
| 16 |
NCT01148290 |
Completed |
Tension-free Vaginal Tape (TVT) Versus Bulking Agent for the Treatment of Post Vulvectomy Urinary Incontinence |
- Urinary Incontinence, Stress
|
- Procedure: Tension free vaginal tape
- Procedure: Bulking agent injection
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cure rate
- Intra-operative complication rate
- Postoperative complication rate
- (and 4 more...)
|
40 |
Female |
18 Years to 95 Years (Adult, Older Adult) |
NCT01148290 |
03/2010 |
|
May 2009 |
September 2012 |
April 2013 |
June 22, 2010 |
April 8, 2013 |
|
- Pugliese Hospital
Catanzaro, Italy
|
|
| 17 |
NCT00476476 |
Completed
Has Results |
Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar |
|
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Genentech, Inc.
- Beth Israel Deaconess Medical Center
- (and 3 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
41 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00476476 |
06-174 |
|
December 2006 |
October 2012 |
October 2012 |
May 22, 2007 |
May 7, 2015 |
March 19, 2015 |
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - Women and Infants Hospital of Rhode Island
Providence, Rhode Island, United States
|
|
| 18 |
NCT01986725 |
Completed |
The Impact of the "WOMAN-PRO II Program" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence |
- Vulvar Cancer
- Vulvar Intraepithelial Neoplasia
|
- Behavioral: standardized care (Intervention I)
- Behavioral: Standardized care + WOMAN-PRO II program (Intervention II)
|
Interventional
|
Phase 2 |
- St.Gallen University of Applied Sciences
- University Hospital Inselspital, Berne
- University Hospital, Basel, Switzerland
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Supportive Care
|
- Changes in symptom prevalence
- Changes in symptom severity
- Changes in Uncertainty-Mishel Uncertainty in Illness Scale (MUIS)
- (and 10 more...)
|
45 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01986725 |
WOMAN-PRO II program |
WOMAN-PROII |
September 2013 |
November 2015 |
November 2015 |
November 18, 2013 |
January 7, 2016 |
|
- Institute for Applied Nursing Sciences IPW, University of Applied Sciences FHS St. Gallen, Switzerland
St. Gallen, Switzerland
|
|
| 19 |
NCT01738152 |
Active, not recruiting |
Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms on Vulvovaginal Health |
- Breast Cancer
- Endometrial Cancer
|
- Other: HLA vaginal gel (HyaloGYN®),
- Behavioral: questionnaires
|
Interventional
|
Not Applicable |
- Memorial Sloan Kettering Cancer Center
- Memorial Sloan Kettering Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- investigate feasibility of conducting a 12-week HLA treatment regimen
- Vaginal Assessment Composite Score [VAS]
- Vulvar Assessment Composite Score [VuAS]
|
106 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01738152 |
12-232 |
|
November 2012 |
November 2018 |
November 2018 |
November 30, 2012 |
February 23, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
|
| 20 |
NCT01806350 |
Completed |
Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors |
- Cervical Cancer
- Endometrial Cancer
- Ovarian Epithelial Cancer
- (and 3 more...)
|
- Other: questionnaire administration
- Procedure: standard follow-up care
- Other: educational intervention
|
Interventional
|
Not Applicable |
- New Mexico Cancer Care Alliance
- National Cancer Institute (NCI)
- New Mexico Cancer Care Alliance
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Improvement in the Patient Global Impression of Improvement (PGI-I) rating
- Changes in the Incontinence Severity Index (ISI) score
- Changes in Urinary Distress Inventory (UDI)
- Changes in Incontinence Impact Questionnaire (IIQ), which measures the impact of urinary incontinence on quality of life
|
40 |
Female |
30 Years and older (Adult, Older Adult) |
NCT01806350 |
INST 0912
NCI-2012-01319 |
|
November 2009 |
September 2012 |
September 2012 |
March 7, 2013 |
March 7, 2013 |
|
- University of New Mexico Cancer Center
Albuquerque, New Mexico, United States
|
|
| 21 |
NCT01047345 |
Completed
Has Results |
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) |
- Cervical Cancers
- Vulvar Cancers
- Vaginal Cancers
- Genital Warts
|
- Biological: V503
- Biological: Placebo to V503
|
Interventional
|
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Percentage of Participants Who Experience an Injection-site Adverse Event (AE) - Base Study
- Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC) - Base Study
- Percentage of Participants Who Experience a Systemic AE - Base Study
- (and 4 more...)
|
924 |
Female |
12 Years to 26 Years (Child, Adult) |
NCT01047345 |
V503-006
2010_504 |
|
February 24, 2010 |
June 10, 2011 |
November 28, 2015 |
January 12, 2010 |
April 21, 2017 |
December 22, 2014 |
|
|
| 22 |
NCT02834013 |
Recruiting |
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
- Acinar Cell Carcinoma
- Adenoid Cystic Carcinoma
- Adrenal Cortex Carcinoma
- (and 82 more...)
|
- Procedure: Biospecimen Collection
- Biological: Ipilimumab
- Biological: Nivolumab
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (ORR) defined as confirmed and unconfirmed complete and partial response
- Incidence of adverse events graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Best response calculated from the sequence of RECIST 1.1 and immune-related response criteria (irRC) objectives
- (and 3 more...)
|
707 |
All |
18 Years and older (Adult, Older Adult) |
NCT02834013 |
NCI-2016-01041
S1609
U10CA180888 |
|
January 13, 2017 |
August 31, 2020 |
|
July 15, 2016 |
June 21, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - (and 828 more...)
|
|
| 23 |
NCT00381888 |
Completed
Has Results |
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer |
- Cervical Cancer
- Endometrial Cancer
- Fallopian Tube Cancer
- (and 5 more...)
|
- Drug: fondaparinux sodium
|
Interventional
|
Phase 2 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Patients With Venous Thromboembolism at Week 4
- Number of Patients Who Achieved Thromboembolism Prophylaxis at Week 4.
|
44 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00381888 |
CDR0000503985
UMN-2006LS009
UMN-0603M82707 |
|
January 2007 |
January 2009 |
January 2009 |
September 28, 2006 |
December 28, 2017 |
January 27, 2010 |
- Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States - Crozer-Chester Medical Center
Upland, Pennsylvania, United States
|
|
| 24 |
NCT02993900 |
Recruiting |
Image-Guided Gynecologic Brachytherapy |
- Cervical Cancer
- Uterine Cancer
- Vaginal Cancer
- (and 2 more...)
|
- Device: Image-Guided Brachytherapy
|
Interventional
|
Phase 2 |
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dosing changes
- The rate of treatment-related toxicity
- Time to local failure
- Rate of survival
|
54 |
Female |
18 Years to 100 Years (Adult, Older Adult) |
NCT02993900 |
J1660
IRB00098525 |
|
September 2016 |
September 2021 |
|
December 15, 2016 |
December 12, 2017 |
|
- The SKCCC at Johns Hopkins
Baltimore, Maryland, United States
|
|
| 25 |
NCT01399658 |
Active, not recruiting |
Image-Guided Gynecologic Brachytherapy |
- Cervical Cancer
- Uterine Cancer
- Vaginal Cancer
- Carcinoma of the Vulva
|
- Procedure: Image-guided brachytherapy
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Dana-Farber Cancer Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose determination
- Toxicities: gastrointestinal, genitourinary, and skin
|
93 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01399658 |
11-098 |
AMIGO |
September 2011 |
February 2017 |
|
July 22, 2011 |
August 11, 2016 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States
|
|
| 26 |
NCT03045172 |
Active, not recruiting |
Platelet Rich Plasma (PRP) for Vulvar Lichen Sclerosus |
- Lichen Sclerosus of Vulva
|
- Biological: Platelet Rich Plasma
- Drug: Saline
|
Interventional
|
Not Applicable |
- Center for Vulvovaginal Disorders
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Clinical Scoring System for Vulvar Lichen Sclerosus
|
29 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03045172 |
GCRF-1 |
|
November 2016 |
June 2018 |
June 2018 |
February 7, 2017 |
May 7, 2018 |
|
- The Center for Vulvovaginal Disorders
Washington, District of Columbia, United States
|
|
| 27 |
NCT03158220 |
Active, not recruiting |
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) |
- Cervical Cancer
- Vulvar Cancer
- Vaginal Cancer
- (and 2 more...)
|
|
Interventional
|
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Anti-HPV Geometric Mean Titers
- Adverse Events
- Study Discontinuations Due to an Adverse Event
- (and 3 more...)
|
1200 |
Female |
16 Years to 45 Years (Child, Adult) |
NCT03158220 |
V503-004 |
|
September 20, 2017 |
November 23, 2018 |
November 23, 2018 |
May 18, 2017 |
March 13, 2018 |
|
- Universitatsklinik fuer Frauenheilkunde und Geburtshilfe ( Site 0002)
Graz, Austria - Klin. Abtlg. fuer Gynaekologie und Geburtshilfe ( Site 0001)
Wien, Austria - Universitair Ziekenhuis Antwerpen ( Site 0007)
Edegem, Belgium - (and 21 more...)
|
|
| 28 |
NCT00520598 |
Completed |
Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) |
- Cervical Cancer
- Vulvar Cancer
- Vaginal Cancer
- (and 2 more...)
|
- Biological: Comparator: V505 formulation 1
- Drug: Comparator: V505 formulation 2
- Biological: Comparator: V505 formulation 3
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Geometric mean titers (GMTs) to HPV types contained in the vaccines administered in a 3-dose regimen
- Geometric mean titers (GMTs) to HPV types contained in the vaccines administered in a 2-dose regimen
|
511 |
Female |
16 Years to 26 Years (Child, Adult) |
NCT00520598 |
V505-001
2007_567 |
|
October 2007 |
May 2011 |
May 2011 |
August 24, 2007 |
November 26, 2015 |
|
|
|
| 29 |
NCT00004074 |
Completed |
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu |
- Advanced Adult Primary Liver Cancer
- Anaplastic Thyroid Cancer
- Bone Metastases
- (and 124 more...)
|
- Biological: recombinant interleukin-12
- Biological: ABI-007/carboplatin/trastuzumab
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 2.0 (CTCAE v2.0)
|
15 |
All |
18 Years and older (Adult, Older Adult) |
NCT00004074 |
NCI-2012-01398
99H0185
U01CA076576
CDR0000067282 |
|
August 1999 |
February 2009 |
|
October 29, 2003 |
February 28, 2013 |
|
- Ohio State University Medical Center
Columbus, Ohio, United States
|
|
| 30 |
NCT02458001 |
Unknown † |
Developing a Stepped Approach to Improving Sexual Function aFteR Treatment fOr gyNaecological Cancer |
- Cervical Cancer
- Ovarian Cancer
- Uterine Cancer
- (and 3 more...)
|
- Behavioral: SAFFRON stepped care
|
Interventional
|
Not Applicable |
- University College, London
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of recruitment
- Consent rate to randomization and treatment
- Proportion of women stepping up from level 1 to 2, and level 2 to 3
- (and 4 more...)
|
100 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02458001 |
HTA 11/111/02 |
SAFFRON |
July 2015 |
March 2017 |
March 2017 |
May 29, 2015 |
May 29, 2015 |
|
|
|
| 31 |
NCT00393263 |
Completed |
Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus |
|
- Drug: pimecrolimus and clobetasol
- Drug: clobetasol 0.05% cream
|
Interventional
|
Phase 2 |
- Center for Vulvovaginal Disorders
- Novartis
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in inflammation
- Pruritus
- Burning
- (and 2 more...)
|
38 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00393263 |
CASM981C US40 |
|
October 2006 |
October 2009 |
October 2009 |
October 27, 2006 |
May 12, 2014 |
|
- Center for VulvoVaginal Disorders
Washington, District of Columbia, United States
|
|
| 32 |
NCT00033605 |
Completed |
Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis |
- Cervical Cancer
- Colorectal Cancer
- Diarrhea
- (and 8 more...)
|
- Drug: octreotide acetate
- Other: placebo
- Radiation: radiation
|
Interventional
|
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Supportive Care
|
- Reduction of diarrhea as measured by NCI CTC version 2.0 weekly during pelvic radiotherapy
- Reduction of patient-reported bowel dysfunction as assessed by the bowel function questionnaire weekly during radiotherapy, weekly for 4 weeks after radiotherapy, and 12 and 24 months after completion of radiotherapy
- Toxicity as assessed by NCI CTC version 2.0 weekly during pelvic radiotherapy
- Importance that patients attach to various measures of bowel dysfunction as assessed by questionnaire at week 4 of radiotherapy and at 12 and 24 months after completion of radiotherapy
|
130 |
All |
18 Years and older (Adult, Older Adult) |
NCT00033605 |
NCCTG-N00CA
CDR0000069304
NCI-P02-0221 |
|
April 2002 |
July 2006 |
July 2006 |
January 27, 2003 |
July 13, 2016 |
|
|
|
| 33 |
NCT02858310 |
Recruiting |
E7 TCR T Cells for Human Papillomavirus-Associated Cancers |
- Papillomavirus Infections
- Cervical Intraepithelial Neoplasia
- Carcinoma In Situ
- (and 2 more...)
|
- Biological: E7 TCR cells
- Drug: aldesleukin
- Drug: fludarabine
- Drug: cyclophosphamide
|
Interventional
|
Phase 1
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase I: Determine a safe dose for E7 TCR cells plus aldesleukin with or without pembrolizumab
- Phase II: Determine effficacy of E7 TCR cells plus aldesleukin
|
180 |
All |
18 Years to 66 Years (Adult, Older Adult) |
NCT02858310 |
160154
16-C-0154 |
|
August 4, 2016 |
December 31, 2020 |
January 1, 2026 |
August 8, 2016 |
June 8, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
|
| 34 |
NCT01313104 |
Withdrawn |
Colposcopy and High Resolution Anoscopy in Screening For Anal Dysplasia in Patients With Cervical, Vaginal, or Vulvar Dysplasia or Cancer |
- Cervical Intraepithelial Neoplasia Grade 1
- Cervical Intraepithelial Neoplasia Grade 2
- Cervical Intraepithelial Neoplasia Grade 3
- (and 22 more...)
|
- Procedure: colposcopy
- Other: cervical Papanicolaou test
- Procedure: screening method
|
Interventional
|
Not Applicable |
- Northwestern University
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Risk of anal dysplasia in women with cervical or vulvar dysplasia
- HPV (Human Papillomavirus) status
|
0 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01313104 |
NU 10G02
NCI-2011-00112
STU00039225 |
|
|
|
|
March 11, 2011 |
June 11, 2012 |
|
|
|
| 35 |
NCT00943722 |
Active, not recruiting
Has Results |
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) |
- Cervical Cancers
- Vulvar Cancer
- Vaginal Cancer
- (and 3 more...)
|
|
Interventional
|
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] Versus 16- to 26-Year-Old Females [Lot 1])
- GMTs for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Males [Lot 1] Versus 16- to 26-Year-Old Females [Lot 1])
- GMTs for Each of the HPV Types Contained in the Vaccine (Lot Consistency Study)
- (and 6 more...)
|
3074 |
All |
9 Years to 26 Years (Child, Adult) |
NCT00943722 |
V503-002
2009_611 |
|
August 27, 2009 |
April 30, 2011 |
December 3, 2020 |
July 22, 2009 |
October 16, 2017 |
January 13, 2015 |
|
|
| 36 |
NCT02096783 |
Completed |
Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer |
- Anxiety Disorder
- Cervical Cancer
- Endometrial Cancer
- (and 8 more...)
|
- Other: informational intervention
- Other: counseling intervention
- Other: questionnaire administration
|
Interventional
|
Not Applicable |
- University of Wisconsin, Madison
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Supportive Care
|
- Feasibility of patient recruitment
- Resumption of sexual activity after cancer surgery
- Retention
- (and 5 more...)
|
15 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02096783 |
UW13080
NCI-2014-00471
P30CA014520 |
|
September 2014 |
June 2015 |
June 2016 |
March 26, 2014 |
November 3, 2016 |
|
- University of Wisconsin, Madison
Madison, Wisconsin, United States
|
|
| 37 |
NCT01376349 |
Active, not recruiting
Has Results |
Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms |
- Breast Cancer
- Gynecologic Cancer
|
- Drug: prasterone
- Other: placebo
|
Interventional
|
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Mayo Clinic
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Supportive Care
|
- Alleviation of the Most Bothersome Vaginal Symptom (Vaginal Dryness or Dyspareunia) Over 12 Weeks
|
464 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01376349 |
NCCTG-N10C1
CDR0000702003
NCI-2011-02677 |
|
July 2011 |
August 2013 |
|
June 20, 2011 |
August 25, 2017 |
August 25, 2017 |
- Mayo Clinic Scottsdale
Scottsdale, Arizona, United States - Aurora Presbyterian Hospital
Aurora, Colorado, United States - Boulder Community Hospital
Boulder, Colorado, United States - (and 277 more...)
|
|
| 38 |
NCT03051516 |
Recruiting |
HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions |
- High Grade Anal Canal Squamous Intraepithelial Neoplasia
- Vulvar High Grade Squamous Intraepithelial Lesion
|
- Other: Laboratory Biomarker Analysis
- Other: Placebo
- Other: Questionnaire Administration
- Biological: Recombinant Human Papillomavirus Nonavalent Vaccine
|
Interventional
|
Phase 4 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
- Fred Hutchinson Cancer Research Center
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to recurrence of anogenital high grade squamous intraepithelial lesion (HSIL)
- Frequency of high grade squamous intraepithelial lesion (HSIL) recurrence
- Human papillomavirus (HPV) antibody level
- (and 2 more...)
|
345 |
All |
27 Years to 69 Years (Adult, Older Adult) |
NCT03051516 |
9790
NCI-2017-00151
P30CA015704
R01CA213130 |
|
July 18, 2017 |
December 21, 2021 |
December 21, 2021 |
February 13, 2017 |
November 17, 2017 |
|
- Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 39 |
NCT03180294 |
Recruiting |
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer |
- Breast Carcinoma
- Cervical Carcinoma
- Ovarian Carcinoma
- (and 4 more...)
|
- Drug: Bupropion Hydrochloride
- Other: Placebo
|
Interventional
|
Phase 2 |
- NRG Oncology
- National Cancer Institute (NCI)
- NRG Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Supportive Care
|
- Change in sexual desire, as measured by the desire subscale of the female sexual function index
- Depressive mood as measured by the patient health questionnaire-4
- Fatigue as measured by Patient Reported Outcomes Measurement Information System fatigue scale
- (and 3 more...)
|
234 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03180294 |
NRG-CC004
NCI-2017-00344
UG1CA189867 |
|
May 31, 2017 |
October 30, 2019 |
May 31, 2027 |
June 8, 2017 |
April 24, 2018 |
|
- Kaiser Permanente-Anaheim
Anaheim, California, United States - Kaiser Permanente-Deer Valley Medical Center
Antioch, California, United States - Kaiser Permanente-Baldwin Park
Baldwin Park, California, United States - (and 298 more...)
|
|
| 40 |
NCT03277482 |
Recruiting |
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer |
- Recurrent Gynecological Cancer
- Metastatic Cervical Cancer
- Metastatic Ovarian Cancer
- (and 8 more...)
|
- Drug: Durvalumab
- Drug: Tremelimumab
- Radiation: Radiation Therapy
|
Interventional
|
Phase 1 |
- Dana-Farber Cancer Institute
- AstraZeneca
- Dana-Farber Cancer Institute
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Radiotherapy with durvalumab and tremelimumab
- Overall Response Rate
- Local Response Rate
- (and 5 more...)
|
32 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03277482 |
17-382 |
|
February 6, 2018 |
January 1, 2020 |
November 1, 2020 |
September 11, 2017 |
April 11, 2018 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 41 |
NCT00003704 |
Completed |
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer |
|
- Drug: capecitabine
- Radiation: radiation therapy
|
Interventional
|
Phase 1 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
51 |
All |
18 Years and older (Adult, Older Adult) |
NCT00003704 |
NCCTG-984652
CDR0000066811 |
|
April 1999 |
July 2003 |
July 2003 |
March 15, 2004 |
July 6, 2016 |
|
- CCOP - Scottsdale Oncology Program
Scottsdale, Arizona, United States - CCOP - Carle Cancer Center
Urbana, Illinois, United States - CCOP - Cedar Rapids Oncology Project
Cedar Rapids, Iowa, United States - (and 15 more...)
|
|
| 42 |
NCT01393470 |
Enrolling by invitation |
Evaluation of Long-term HPV Vaccine Efficacy |
|
- Procedure: Screening for cervical cancer
|
Observational
|
|
- University of Tampere
- FinnMedi Oy
- GlaxoSmithKline
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Occurrence of intraepithelial neoplasia grade 3 or worse (CIN3+). including CIN3, cervical cancer (squamous cell carcinoma or adenocarcinoma).
- Occurrence of potentially HPV related non-cervical cancers or pre cancerous lesions, including but not limited to the occurrence of vulvar intraepithelial neoplasia and vaginal intraepithelial neoplasia.
|
10000 |
Female |
16 Years to 19 Years (Child, Adult) |
NCT01393470 |
115006 (HPV-027) |
|
May 2011 |
December 2024 |
December 2024 |
July 13, 2011 |
May 15, 2014 |
|
- Väestöliitto Seksuaaliterveysklinikka
Helsinki, Finland - Nuorten rokotetutkimukset
Jyväskylä, Finland - Nuorten rokotetutkimukset
Kotka, Finland - (and 12 more...)
|
|
| 43 |
NCT03267680 |
Recruiting |
IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3 |
- Cervical Squamous Cell Carcinoma In Situ
- Vulvar High Grade Squamous Intraepithelial Lesion
|
- Drug: Cyclophosphamide
- Drug: Indomethacin
- Biological: IRX-2
- (and 5 more...)
|
Interventional
|
Phase 2 |
- University of Southern California
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Pathologic response
- Incidence of adverse events of IRX-2 administration
|
60 |
Female |
25 Years and older (Adult, Older Adult) |
NCT03267680 |
5GYN-16-2
NCI-2017-01402
P30CA014089 |
|
November 8, 2017 |
November 8, 2021 |
November 8, 2022 |
August 30, 2017 |
November 17, 2017 |
|
- USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
|
|
| 44 |
NCT00275353 |
Completed |
Effectiveness of an Individualized Symptom Education Program (ISEP) |
- Uterine Cancer
- Cervical Cancer
- Vaginal Cancer
- Vulvar Cancer
|
- Behavioral: Individualized Symptom Education
|
Interventional
|
Phase 2 |
- University of Toronto
- Canadian Cancer Trials Group
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single
- Primary Purpose: Treatment
|
- Symptom distress - measured by the Symptom Distress Scale (SDS) at baseline, end of treatment, and three (3) months post treatment.
- All secondary outcomes measured at baseline, end of treatment, and three (3) months post treatment.
- Pain - measured by the Brief Pain Inventory–Short Form (BPI-SF)
- (and 4 more...)
|
144 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00275353 |
9848
014144
14927
12048
266-2003
03-0487-CE |
|
July 2003 |
|
February 2006 |
January 11, 2006 |
May 26, 2006 |
|
- Princess Margaret Hospital; Toronto Sunnybrook Reginal Cancer Centre
Toronto, Ontario, Canada
|
|
| 45 |
NCT02488759 |
Recruiting |
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors |
|
- Drug: Nivolumab
- Drug: Ipilimumab
- Drug: BMS-986016
- Drug: Daratumumab
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The safety and tolerability will be measured by the incidence of drug-related adverse events (AEs) and serious adverse events (SAEs)
- Objective response rate
- Rate of surgery delay
- (and 5 more...)
|
500 |
All |
18 Years and older (Adult, Older Adult) |
NCT02488759 |
CA209-358
2015-000230-29 |
CheckMate358 |
October 8, 2015 |
May 13, 2019 |
December 31, 2019 |
July 2, 2015 |
May 22, 2018 |
|
- H. Lee Moffitt Cancer Center
Tampa, Florida, United States - Winship Cancer Institute
Atlanta, Georgia, United States - Local Institution
New Orleans, Louisiana, United States - (and 41 more...)
|
|
| 46 |
NCT00601406 |
Unknown † |
Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer |
- Breast Cancer
- Cervical Cancer
- Endometrial Cancer
- (and 7 more...)
|
- Genetic: gene expression analysis
- Genetic: gene rearrangement analysis
- Genetic: polymorphism analysis
- (and 2 more...)
|
Interventional
|
Not Applicable |
- The Christie NHS Foundation Trust
- National Cancer Institute (NCI)
|
Other |
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Correlation of association between common genetic variations, reported by single nucleotide polymorphisms (SNP) in relevant candidate genes, with individual patient variability in normal tissue radiation response and toxicity
- Comparison of different clinical scoring systems for late normal tissue effects
- Comparison of clinical scoring systems with analytical measures of normal tissue outcome using volume change in the breast measured by laser camera
- (and 4 more...)
|
2200 |
All |
Child, Adult, Older Adult |
NCT00601406 |
CDR0000581139
CHNT-RAPPER
EU-20798 |
|
March 2006 |
February 2008 |
|
January 28, 2008 |
August 26, 2013 |
|
- Sussex Cancer Centre at Royal Sussex County Hospital
Brighton, England, United Kingdom - Bristol Haematology and Oncology Centre
Bristol, England, United Kingdom - Addenbrooke's Hospital
Cambridge, England, United Kingdom - (and 8 more...)
|
|
| 47 |
NCT02412124 |
Terminated |
Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers |
- Cervical Carcinoma
- Ovarian Carcinoma
- Uterine Corpus Cancer
- (and 2 more...)
|
- Procedure: Supportive Care
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
|
Interventional
|
Not Applicable |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Change in quality of life benefits for patients, as assessed by the FACT-G
- Satisfaction of patients with the timing, content, and format of the program, as assessed by the W2W Patient Survey
- Satisfaction of mentors with the timing, content, and format of the program, as assessed by the W2W Volunteer/Mentor Survey
- (and 2 more...)
|
3 |
Female |
19 Years and older (Adult, Older Adult) |
NCT02412124 |
14359
NCI-2015-00467 |
|
July 2015 |
April 2018 |
April 2018 |
April 8, 2015 |
May 10, 2018 |
|
- City of Hope Medical Center
Duarte, California, United States
|
|
| 48 |
NCT01216813 |
Completed |
Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer |
- Adenocarcinoma of the Gastroesophageal Junction
- Cervical Cancer
- Endometrial Cancer
- (and 7 more...)
|
- Other: informational intervention
- Procedure: assessment of therapy complications
- Procedure: psychosocial assessment and care
|
Observational
|
|
- Royal Marsden NHS Foundation Trust
- National Cancer Institute (NCI)
|
Other |
|
- Patients' perspective of their physical and psychosocial rehabilitation needs following their diagnosis and treatment
- Patients' experiences of the physical and social impact of cancer in the treatment and post-treatment phase
- Patients' met and un-met needs
- (and 2 more...)
|
33 |
All |
18 Years to 120 Years (Adult, Older Adult) |
NCT01216813 |
CDR0000686456
RMNHS-REHABILITATION
EU-21074
RMNHS-CCR3434
MREC-10/H0806/56 |
|
August 2010 |
October 2010 |
December 2010 |
October 7, 2010 |
November 1, 2016 |
|
- Royal Marsden - London
London, England, United Kingdom
|
|
| 49 |
NCT01079832 |
Completed
Has Results |
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies |
- Fallopian Tube Cancer
- Ovarian Sarcoma
- Ovarian Stromal Cancer
- (and 23 more...)
|
- Radiation: stereotactic radiosurgery
- Procedure: quality-of-life assessment
|
Interventional
|
Phase 2 |
- Case Comprehensive Cancer Center
- National Cancer Institute (NCI)
- Case Comprehensive Cancer Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Acute Toxicity Rate
- Disease-free Survival
- Median Overall Survival
- (and 2 more...)
|
50 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01079832 |
CASE13808
NCI-2010-00285 |
|
May 2009 |
May 2012 |
May 2012 |
March 3, 2010 |
November 28, 2013 |
November 28, 2013 |
- Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
|
| 50 |
NCT00019110 |
Completed |
Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer |
- Anal Cancer
- Cervical Cancer
- Esophageal Cancer
- (and 3 more...)
|
- Biological: human papillomavirus 16 E7 peptide
- Biological: synthetic human papillomavirus 16 E6 peptide
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Primary Purpose: Treatment
|
|
|
Female |
18 Years and older (Adult, Older Adult) |
NCT00019110 |
CDR0000064330
NCI-95-C-0154
NCI-T94-0134N |
|
November 1995 |
|
|
January 27, 2003 |
April 29, 2015 |
|
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Bethesda, Maryland, United States - Center for Cancer Research
Bethesda, Maryland, United States - Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States - (and 3 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: